Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-07-12
2005-07-12
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S183000
Reexamination Certificate
active
06916815
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
REFERENCES:
patent: 778 277 (1997-06-01), None
patent: WO 98/08847 (1998-03-01), None
patent: WO 01/14378 (2001-03-01), None
patent: WO 02/40486 (2002-05-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
Otter et al., “Conformational Properties of Purine-Like C-Nucleosides”, Nucleoside & Nucleotides, vol. 15, Nos. 1-3, pp. 793-807 (1996).
Quintella et al., “A Ready One-Pot Preparation for Pyrrolo [2,1-fl-[1,2,4] Triazine and Pyrazolo[5,1-c]Pyramidol[4,5-e]-[1,2,4]Triazine Derivatives”, Tetrahedron, vol. 52, No. 8, pp. 3037-3048 (1996).
Patil et al., “Synthesis of Pyrrolo [2,1-f][1,2,4] Triazine Congeners of Nucleic Acid Purines via the N-Amination of 2-Substituted Pyrroles [1]”, J. Heterocyclic Chem. vol. 31, No. 4, 781-807 (1994).
Neunhoeffer et al., “Cycloadditionen mit Methoxy-und Dialkylamino-1,2,4-Triazinen”, Justus Liebigs Ann. Chem., vol. 9, pp. 1413-1420 (1977) & Chem. Abstract 88:121113q, (1978).
Skobe et al., “Halting Angiogenesis Suppresses Carcinoma Cell Invasion”. Nature Medicine, vol. 3, No. 11, pp. 1223-1227 (1997).
Fink Brian E.
Gavai Ashvinikumar V.
Kadow John F.
Mastalerz Harold
Vite Gregory D.
Balasubramanian Venkataraman
Bristol--Myers Squibb Company
Korsen Elliott
LandOfFree
C-6 modified indazolylpyrrolotriazines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with C-6 modified indazolylpyrrolotriazines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and C-6 modified indazolylpyrrolotriazines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3368562